BMS 599626

Drug Profile

BMS 599626

Alternative Names: AC480; BMS599626

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ambit Biosciences Corporation; Bristol-Myers Squibb
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Glioma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jul 2015 Discontinued - Phase-I for Breast cancer, Glioma, Non-small cell lung cancer and Solid tumours (Combination therapy) in USA after October 2013 (IV)
  • 22 Jun 2015 Ambit Biosciences withdraws phase-I trial in Solid tumours in USA prior to enrolment (Combination therapy) (NCT01245543)
  • 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top